FDA Advisory Cmte. Material Disclosure To Debut With Bayer ProMem Review
Executive Summary
Bayer's ProMem and Immunex' Novantrone will be the first drugs to have advisory committee information packages publicly released.
You may also be interested in...
Bayer Promem
FDA's Peripheral & Central Nervous System Drugs Advisory Committee will review metrifonate (NDA 20-914) for treatment of mild to moderate dementia of the Alzheimer's type on Jan. 27. The following day, the committee will review Immunex' Novantrone (mitoxantrone, NDA 21-120) for treatment of secondary progressive multiple sclerosis ("The Pink Sheet" Dec. 13, 1999, p. 22). The meeting begins at 8:00 a.m. at the Hilton in Gaithersburg, Md. on both days
Advisory Cmte. Package Redaction Could Add Two Months To Priority Review
A drug receiving six-month priority review could have its review time extended by up to two months if its sponsor requests redaction of the advisory committee package, FDA said in a draft guidance.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011